4.7 Article

Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer

期刊

JOURNAL OF EXTRACELLULAR VESICLES
卷 12, 期 7, 页码 -

出版社

WILEY
DOI: 10.1002/jev2.12338

关键词

ADAM17; ascites; chemoresistance; extracellular vesicles; ovarian cancer

向作者/读者索取更多资源

Ovarian cancer (OvCa) is a gynecological disorder with poor prognosis due to fast development of chemoresistance. This study reveals that cancer cell-derived extracellular vesicles (EV) play a role in sustaining chemoresistance through the release of active ADAM17 which promotes tumor cell proliferation and survival via the EGFR pathway.
Ovarian cancer (OvCa) is the gynaecological disorder with the poorest prognosis due to the fast development of chemoresistance. We sought to connect chemoresistance and cancer cell-derived extracellular vesicles (EV). The mechanisms of how chemoresistance is sustained by EV remained elusive. One potentially contributing factor is A Disintegrin and Metalloprotease 17 (ADAM17)-itself being able to promote chemoresistance and inducing tumour cell proliferation and survival via the Epidermal Growth Factor Receptor (EGFR) pathway by shedding several of its ligands including Amphiregulin (AREG). We now demonstrate that upon chemotherapeutic treatment, proteolytically active ADAM17 is released in association with EV from OvCa cells. In terms of function, we show that patient-derived EV induce AREG shedding and restore chemoresistance in ADAM17-deficient cells. Confirming that ADAM17-containing EV transmit chemoresistance in OvCa, we propose that ADAM17 levels (also on EV) might serve as an indicator for tumour progression and the chemosensitivity status of a given patient.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据